동향
Home > DB > 동향
| COMPLIANCE POLICY GUIDE RADIOPHARMACEUTICAL COMPOUNDING | |||
|---|---|---|---|
| 분류 | Radiopharmaceuticals | 조회 | 2421 |
| 발행년도 | 2013 | 등록일 | 2015-10-02 |
| 출처 | CORAR (바로가기) | ||
|
Section 503A was added to the Federal Food, Drug, and Cosmetic Act (FDC Act) by the Food and Drug Administration Modernization Act of 1997. Section 503A describes conditions that must be satisfied in order for drug products compounded by a licensed pharmacist or licensed physician to be exempt from certain requirements of the FDC Act.
(후략)
|
|||
|
|
 이전글 |
Interventional Optical Molecular Imaging Guidance during Percutaneous Biopsy |
|---|---|
 다음글 |
Guidelines for phase 1 clinical trials |
